Ula1 Inhibitors
Chemical inhibitors of Ula1 include a variety of compounds that can interfere with its role in the incorporation of selenocysteine during translation. Trichostatin A, a histone deacetylase inhibitor, can alter the acetylation status of proteins involved in the translation machinery, which can affect Ula1's function. Similarly, C646 can inhibit the acetyltransferase activity of p300/CBP, potentially leading to decreased acetylation levels of proteins that interact with or regulate Ula1, thereby affecting its activity. Bortezomib and Epoxomicin, both proteasome inhibitors, can lead to an accumulation of proteins that are usually marked for degradation, disrupting the cellular environment and indirectly affecting Ula1's function. MG-132 also inhibits proteasome activity, which can cause a build-up of polyubiquitinated proteins, further affecting the cellular milieu in which Ula1 operates.
Additionally, MLN4924 inhibits the NEDD8-activating enzyme, which can affect the neddylation of proteins that are part of the Ula1 pathway, influencing its function. Cycloheximide and Anisomycin interfere with protein biosynthesis, with the former inhibiting the translocation step and the latter inhibiting peptide chain elongation, both of which can reduce the number of nascent proteins requiring Ula1's involvement in selenocysteine incorporation. Puromycin, by causing premature chain termination, can decrease the pool of proteins that reach the stage where Ula1 activity is necessary. Tunicamycin, which blocks N-linked glycosylation, can impact the proper folding and function of glycosylated proteins that are involved with Ula1, indirectly inhibiting its activity. 17-AAG, an Hsp90 inhibitor, can destabilize proteins that interact with the Ula1 pathway, disrupting its function. Finally, Auranofin, by inhibiting thioredoxin reductase, can disrupt the redox state of proteins within the Ula1 pathway, which can affect Ula1's activity in the complex process of selenocysteine incorporation into selenoproteins.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. Ula1 is involved in the process of selenocysteine incorporation during translation, which is a highly regulated process and may involve acetylation as a post-translational modification. By inhibiting histone deacetylase, Trichostatin A could potentially alter the acetylation status of proteins involved in the translation machinery, thereby hindering Ula1's function in selenoprotein synthesis. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. Ula1's function might be regulated by the ubiquitin-proteasome system, as many proteins are. Inhibition of the proteasome by Bortezomib could lead to an accumulation of proteins that are normally degraded, potentially disrupting the cellular environment and indirectly inhibiting Ula1's function in selenocysteine incorporation. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, which is crucial for the neddylation pathway. Since neddylation can regulate protein function and stability, MLN4924 could hinder the neddylation of protein factors that interact with or regulate Ula1, leading to a functional inhibition of Ula1's role in selenoprotein synthesis. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a competitive inhibitor of p300/CBP histone acetyltransferase. Ula1 activity could be regulated by acetylation, thus, inhibition of acetyltransferases by C646 may decrease acetylation levels of proteins involved in Ula1's pathway, thereby inhibiting Ula1's function. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is an inhibitor of eukaryotic protein biosynthesis by interfering with the translocation step in protein synthesis, thus potentially reducing the overall pool of nascent proteins that would require selenocysteine incorporation by Ula1. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature chain termination during protein synthesis by acting as an analog of aminoacyl-tRNA. This could effectively reduce the number of proteins that reach the stage where Ula1 is required for selenocysteine incorporation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin inhibits eukaryotic peptide chain elongation. This inhibition could lead to a decrease in elongating polypeptide chains that require Ula1 for incorporation of selenocysteine. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation. If Ula1 or associated proteins are glycosylated, this could inhibit their proper folding and function, indirectly inhibiting Ula1's activity in selenoprotein synthesis. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is an Hsp90 inhibitor. By inhibiting Hsp90, client proteins that are involved in Ula1-mediated pathways may not be properly folded or stabilized, which could disrupt Ula1's function in the selenocysteine incorporation process. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin is an inhibitor of thioredoxin reductase. Since Ula1 is involved in the selenocysteine incorporation, and selenocysteine is similar to cysteine which is a target for redox regulation, auranofin could disrupt the redox state of proteins involved in Ula1's pathway, thereby inhibiting its function. | ||||||